Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The long answer along with a dosage chart you can find below ... Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist and a GIP agonist, too. Its two main effects make it more ...

In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... and weight loss medicine, Zepbound. However, in mid-January, Lilly ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

In the chart above, you can see financial results ... which is the technical name for both Mounjaro and Zepbound, to see if higher doses than what has currently been approved could be made available.